You are here

Osteoporosis Drugs Market Insights Report, 2019 - Availability of Reimbursement Programs for Patients with Osteoporosis Will Drive Market Growth

DUBLIN, April 18, 2019 /PRNewswire/ -- The "Global Osteoporosis Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The osteoporosis drugs market will register a CAGR of almost 5% by 2023.

The availability of reimbursement programs for patients with osteoporosis will drive the market growth during the forecast period. Osteoporosis is the most prevalent among the geriatric population. Therefore, major markets such as the US, Germany, Japan, the UK, France, Canada, Spain, and other developed European countries are providing reimbursement schemes.

Increasing prevalence of osteoporosis

Osteoporosis prevalence has increased worldwide due to which it is considered a serious public health concern. Osteoporosis is more common in older women than in older men. The improved standards of healthcare facilities and sophisticated treatment options have increased the life expectancy rates, augmenting the aging population

Side effects of osteoporosis drugs

Side effects of bisphosphonates such as alendronate, ibandronate, risedronate, and zoledronic acid may include muscle pain, joint pain, nausea, difficulty swallowing, heartburn, irritation of the esophagus, and gastric ulcers. Also, these drugs can cause osteonecrosis of the jaw. The risk of osteonecrosis of the jaw in an individual increase with treatment periods longer than 5 years.

Competitive Landscape

The market appears to be moderately fragmented and with the presence of several vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Key Players

  • Amgen Inc.
  • Eli Lilly and Company
  • Novartis AG
  • Pfizer Inc.
  • Radius Health Inc.

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Comparison by product
  • Antiresorptive drugs - Market size and forecast 2018-2023
  • Anabolic drugs - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • RoW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amgen Inc.
  • Eli Lilly and Company
  • Novartis AG
  • Pfizer Inc.
  • Radius Health Inc.

For more information about this report visit https://www.researchandmarkets.com/r/vvm4zw

Media Contact:


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:http://www.prnewswire.com/news-releases/osteoporosis-drugs-market-insights-report-2019---availability-of-reimbursement-programs-for-patients-with-osteoporosis-will-drive-market-growth-300834560.html

SOURCE Research and Markets